Picture loading failed.

Anti-IL13 therapeutic antibody (Pre-made Abrezekimab biosimilar,Fab) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Abrezekimab (formerly VR 942) a biologic immunomodulatory product, is being developed by UCB and Vectura Group for the treatment of severe inflammatory.

Order informatioin

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-004-1mg 1mg 3090
GMP-Bios-ab-004-10mg 10mg 21890
GMP-Bios-ab-004-100mg 100mg 148000
GMP-Bios-ab-004-xmg ≥100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-IL13 therapeutic antibody (Pre-made Abrezekimab biosimilar,Fab)
INN Name Abrezekimab
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-I
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2017
Year Recommended2018
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedAsthma
Development Techna